VIA
SMMT icon

Virtus Investment Advisers’s Summit Therapeutics SMMT Stock Holding History

Virtus Investment Advisers’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$340K Buy
23,355
+7,836
+50% +$139K 0.08% 355
2026
Q1 		$294K Buy
15,519
+378
+2% +$6.11K 0.08% 280
2025
Q4 		$265K Buy
15,141
+9,497
+168% +$179K 0.07% 303
2025
Q3 		$117K Buy
5,644
+980
+21% +$23.8K 0.03% 408
2025
Q2 		$99.3K Sell
4,664
-4,528
-49% -$103K 0.03% 337
2025
Q1 		$177K Buy
+9,192
New +$184K 0.05% 273

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Virtus Investment Advisers's SMMT Position: Q2 2026 in Review

Virtus Investment Advisers increased its Summit Therapeutics (SMMT) stake by 50% in Q2 2026, buying an estimated $139K and bringing the position to 23,355 shares worth $340K. The position accounts for 0.08% of the portfolio, ranked #355.

Virtus Investment Advisers first reported a position in SMMT in Q1 2025 and has held it in 6 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Virtus Investment Advisers held 23,355 shares of Summit Therapeutics worth $340K as of Q2 2026.
  • Virtus Investment Advisers bought 7,836 Summit Therapeutics shares in Q2 2026, an estimated $139K.
  • Summit Therapeutics made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #355 holding.
  • Virtus Investment Advisers first reported a position in Summit Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.